New treatment strategy effective for certain lung cancers
March 11th, 2011 - 4:56 pm ICT by ANILondon, March 11 (ANI): Two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients, according to a new study.
Louisiana State University oncologist Vince D. Cataldo and his colleagues say these drugs should be considered as a first-line treatment in people who are known to carry an Epidermal Growth Factor Receptor (EGFR) mutation.
The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.
“Targeting the genetic mutation contributing to the development of the cancer, this class of drugs produced a response rate that exceeded 70pc in these patients,” said Cataldo.
The drugs, taken by mouth, also had fewer side effects. Unlike traditional cytotoxic agents, Erlotinib and Gefitinib do not typically cause myelosuppression, neuropathy, alopecia, or severe nausea.
The study has been published in the March 10, 2011 issue of the New England Journal of Medicine. (ANI)
- Blood test could identify lung cancer patients likely to respond to drug erlotinib - May 01, 2010
- Gefitinib shows promise in treating Asian nonsmokers with lung cancer - Sep 16, 2008
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- Molecular switch that helps pancreatic cancer beat drugs identified - Jan 29, 2010
- India-US team finds new therapy for pancreatic cancer - Dec 30, 2008
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- 'Happy hour' gene may help boozers stay away from alcohol - May 22, 2009
- Adopting 'synthetic lethality' could boost molecularly targeted cancer therapy - Sep 22, 2010
- Cancer drugs offer new hope for Crohn's disease and sarcoidosis - Dec 01, 2010
- Scientists launch groundbreaking tool for personalized treatment of lung cancer - Apr 27, 2008
- Molecule key to non-smoking lung cancer identified - Jul 28, 2009
- Gene mutations help leukemia drug fight squamous cell lung cancer - Apr 04, 2011
- New approach holds promise for pancreatic cancer treatment - Sep 26, 2008
- Most common adult brain cancer associated with gene deletion - Dec 23, 2010
- Now, a disposable device to identify aggressive breast cancers - Sep 29, 2010
Tags: cell lung cancer, cell survival, chemotherapy drugs, cytotoxic agents, england journal of medicine, epidermal growth factor, epidermal growth factor receptor, erlotinib, gefitinib, genetic mutation, growth factor receptor, journal of medicine, london march, louisiana state university, lung cancers, new england journal, new england journal of medicine, non small cell lung cancer, small cell lung cancer, tyrosine kinase inhibitors